Drug Equality Alliance

Last updated

The Drug Equality Alliance is a non-profit organisation based in the United Kingdom whose mission statement is:

Contents

[...] It is made to transform the "War on Some People who use Some Drugs" from its subjective historical and cultural roots into a rational and objective legal regulatory framework that secures equal rights and equal protection to all those who are concerned with dangerous or otherwise harmful drugs. Our mission is to use domestic and international legal jurisdictions to interrogate the law and its application to those who produce, commerce, possess and consume such drugs. [1]

The Drug Equality Alliance believes that the UK Government is administering the Misuse of Drugs Act 1971 in an arbitrary and discriminatory manner. This is contrary to the purpose of the Act, contrary to the original wishes of Parliament, conflicts with the European Convention on Human Rights, and is therefore illegal. It argues that the penalties associated with the possession, production and supply of various controlled substances are not proportional to the relative harms which these substances cause to individuals and society, especially since two of the most dangerous drugs, alcohol and tobacco, are presently excluded from the Act. The Drug Equality Alliance is currently assisting and supporting several legal challenges in relation to this alleged maladministration. [2] [3] [4] [5] [6] [7]

As evidence that the Misuse of Drugs Act 1971 is being administered arbitrarily, the Drug Equality Alliance cites the following admission made by the Government in "The Government Reply to the Fifth Report from the House of Commons Science and Technology Committee Session 2005-6 HC 1031: Drug classification: making a hash of it?" (Cm 6941):

...the Government acknowledges that alcohol and tobacco account for more health problems and deaths than illicit drugs.... The distinction between legal and illegal substances is not unequivocally based on pharmacology, economic or risk benefit analysis. It is also based in large part on historical and cultural precedents. [8]

In March 2010, in response to a Freedom of Information request process submitted by Casey William Hardison, acting with the Drug Equality Alliance, the Information Commissioner's Office ordered the Home Office to disclose a suppressed draft consultation paper with suggestions for a review of the drug classification system. [9] [10] [11] [12] This decision was subject to a last minute appeal by the Home Office, but the appeal was withdrawn on 9 July 2010 and the consultation paper was released on 12 July 2010. [13]

The web address and website of the organisation originated in 2008. The respective web address was last recorded as directing to the organisation's official website up until 6 July 2022. Since 17 October 2022, it has been recorded as either inaccessible or redirecting to other unrelated content to the organisation (such as a gambling website). [14]

See also

Related Research Articles

<span class="mw-page-title-main">Controlled Substances Act</span> United States drug-regulating law

The Controlled Substances Act (CSA) is the statute establishing federal U.S. drug policy under which the manufacture, importation, possession, use, and distribution of certain substances is regulated. It was passed by the 91st United States Congress as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 and signed into law by President Richard Nixon. The Act also served as the national implementing legislation for the Single Convention on Narcotic Drugs.

<span class="mw-page-title-main">Drug prohibition</span> Prohibition of drugs through law

The prohibition of drugs through sumptuary legislation or religious law is a common means of attempting to prevent the recreational use of certain intoxicating substances.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

<span class="mw-page-title-main">Misuse of Drugs Act 1971</span> United Kingdom legislation

The Misuse of Drugs Act 1971 is an act of the Parliament of the United Kingdom. It represents action in line with treaty commitments under the Single Convention on Narcotic Drugs, the Convention on Psychotropic Substances, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.

A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Designer drugs include psychoactive substances that have been designated by the European Union, Australia, and New Zealand, as new psychoactive substances (NPS) as well as analogs of performance-enhancing drugs such as designer steroids.

<span class="mw-page-title-main">Regulation of therapeutic goods</span> Legal management of drugs and restricted substances

The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency. In other jurisdictions they are regulated at the state level, or at both state and national levels by various bodies, as in Australia.

<span class="mw-page-title-main">Benzylpiperazine</span> Recreational drug

Benzylpiperazine (BZP) is a substance often used as a recreational drug and is known to have euphoriant and stimulant properties. Several studies conducted between 2000 and 2011 found that the effects of BZP are similar to amphetamine, although BZP's dosage is roughly 10 times higher by weight.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act, the category reserved for drugs that have "no currently accepted medical use", is a proposed legal and administrative change in cannabis-related law at the federal level. After being proposed repeatedly since 1972, the U.S. Department of Justice initiated 2024 rulemaking to reschedule cannabis to Schedule III of the Controlled Substances Act. The majority of 2024 public comments supported descheduling, decriminalizing, or legalizing marijuana at the federal level.

The Alliance for Cannabis Therapeutics (ACT) is an organization supporting medical marijuana that was founded in 1981 by Robert C. Randall and Alice O'Leary. The Alliance was originally formed through Randall’s personal campaigning to access medical marijuana to treat his glaucoma. After being found not guilty of marijuana possession by reason of medical necessity and being included in a research program in which he received marijuana, Randall was the first person known to have successfully used medical necessity as a defense against a charge of marijuana possession in violation of the Controlled Substances Act. After Randall’s individual success in obtaining marijuana legally, the Alliance for Cannabis Therapeutics sought to drive the movement in politics and public media for widespread medical cannabis usage.

Cannabis classification in the United Kingdom refers to the class of drugs, as determined by the Misuse of Drugs Act 1971, that cannabis is placed in. Between 1928 and 2004 and since 2009, it has been classified as a class B drug. From 2004 to 2009, it was a class C drug. At present, it is a class B, with very limited exceptions.

<span class="mw-page-title-main">Misuse of Drugs Act 1975</span> Act of Parliament in New Zealand

The Misuse of Drugs Act 1975 is a New Zealand drug control law that classifies drugs into three classes, or schedules, purportedly based on their projected risk of serious harm. However, in reality, classification of drugs outside of passing laws, where the restriction has no legal power, is performed by the governor-general in conjunction with the Minister of Health, neither of whom is actually bound by law to obey this restriction.

The Advisory Council on the Misuse of Drugs (ACMD) is a British statutory advisory non-departmental public body, which was established under the Misuse of Drugs Act 1971.

The United Kingdom Misuse of Drugs Act 1971 aimed to control the possession and supply of numerous listed drugs and drug-like substances as a controlled substance. The act allowed and regulated the use of some Controlled Drugs by various classes of persons acting in their professional capacity.

Legal status of <i>Salvia divinorum</i> Psychoactive plant, legal in most countries

Salvia divinorum, a psychoactive plant, is legal in most countries. Exceptions, countries where there is some form of control, include Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Italy, India, Japan, South Korea, Norway, Poland, United Kingdom, Ukraine, Spain, Sweden, Vietnam, Armenia and 33 states and territories of the United States.

Mid-level practitioners, also called non-physician practitioners, advanced practice providers, or commonly mid-levels, are health care providers who assess, diagnose, and treat patients but do not have formal education or certification as a physician. The scope of a mid-level practitioner varies greatly among countries and even among individual practitioners. Some mid-level practitioners work under the close supervision of a physician, while others function independently and have a scope of practice difficult to distinguish from a physician. The legal scope of practice for mid-level practitioners varies greatly among jurisdictions, with some having a restricted and well-defined scope, while others have a scope similar to that of a physician. Likewise, the training requirement for mid-level practitioners varies greatly between and within different certifications and licensures.

<span class="mw-page-title-main">Synthetic cannabinoids</span> Designer drugs

Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids in cannabis plants attach. These novel psychoactive substances should not be confused with synthetic phytocannabinoids or synthetic endocannabinoids from which they are in many aspects distinct.

<span class="mw-page-title-main">Naphyrone</span> Substituted cathinone stimulant drug

Naphyrone, also known as O-2482 and naphthylpyrovalerone, is a substituted cathinone drug derived from pyrovalerone that acts as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), producing stimulant effects and has been reported as a novel designer drug. No safety or toxicity data is available on the drug.

The production, distribution, and sale of methamphetamine is restricted or illegal in many jurisdictions.

The legal status of Salvia divinorum in the United States varies, with 29 states having completely banned it and others considering proposals for banning its use.

Drug class may refer to:

References

  1. ↑ "Drug Equality Alliance (DEA) - Mission Statement". Drugequality.org. Archived from the original on 2011-12-20. Retrieved 2012-01-04.{{cite web}}: CS1 maint: unfit URL (link)
  2. ↑ "Drug Equality Alliance (DEA) - Cases". Drugequality.org. Archived from the original on 2022-03-31. Retrieved 2012-01-04.{{cite web}}: CS1 maint: unfit URL (link)
  3. ↑ "Peter Tatchell: The government is about to face a challenge to its drugs policy | Comment is free | guardian.co.uk". The Guardian. 2011-05-05. Retrieved 2012-01-04.
  4. ↑ "Transform Drug Policy Foundation Blog: Government challenged on drugs law". Transform-drugs.blogspot.com. 2008-10-14. Retrieved 2012-01-04.
  5. ↑ "Teacher in court over drugs | Manchester Evening News - menmedia.co.uk". Manchester Evening News. 2009-03-25. Retrieved 2012-01-04.
  6. ↑ "Cannabis campaigner charged with possession (From Western Telegraph)". Westerntelegraph.co.uk. 2010-01-24. Retrieved 2012-01-04.
  7. ↑ Published on Monday 18 May 2009 10:24 (2009-05-18). "Cannabis test case in court - News". Wigan Today. Archived from the original on 2009-05-20. Retrieved 2012-01-04.{{cite web}}: CS1 maint: numeric names: authors list (link)
  8. ↑ "Drug classification: making a hash of it? CM 6941" (PDF). Retrieved 2012-01-04.
  9. ↑ "Drug Equality Alliance (DEA) - News". Drugequality.org. Archived from the original on 2011-11-19. Retrieved 2012-01-04.{{cite web}}: CS1 maint: unfit URL (link)
  10. ↑ Article title [usurped] [ bare URL PDF ]
  11. ↑ UKCIA in News and comment (2010-03-14). "Government forced to publish consultation paper on the future of drugs classification 2006. | The UKCIA News Blog". Ukcia.org. Archived from the original on 2012-01-08. Retrieved 2012-01-04.
  12. ↑ UKCIA in News and comment (2010-03-15). "Freedom of Information ruling on drug classification proposals | The UKCIA News Blog". Ukcia.org. Archived from the original on 2012-01-08. Retrieved 2012-01-04.
  13. ↑ "Mark Easton's UK: Tension at heart of drug classification". BBC. 2010-07-12. Retrieved 2012-01-04.
  14. ↑ "Website archive calendar for drugequality.org". Wayback Machine. Retrieved 23 June 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.